
**DOI link**

https://doi.org/10.1093/ageing/afx150

**ePrints link**

http://eprint.ncl.ac.uk/242336

**Date deposited**

28/03/2018

**Embargo release date**

04/09/2018

**Copyright**

This is a pre-copyedited, author-produced version of an article accepted for publication in *Age and Ageing* following peer review. The version of record is available online at: https://doi.org/10.1093/ageing/afx150
New Horizons in Multimorbidity in Older Adults

Abstract

The concept of multimorbidity has attracted growing interest over recent years, and more latterly with the publication of specific guidelines on multimorbidity by the National Institute for Health and Care Excellence (NICE). Increasingly it is recognised that this is of particular relevance to practitioners caring for older adults, where multimorbidity may be more complex due to the overlap of physical and mental health disorders, frailty and polypharmacy. The overlap of frailty and multimorbidity in particular is likely to be due to the widespread health deficit accumulation, leading in some cases to functional impairment. The National Institute for Health and Care Excellence (NICE) guidelines identify ‘target groups’ who may benefit from a tailored approach to care that takes their multimorbidity into account, and make a number of research recommendations. Management includes a proactive individualised assessment and care plan, which improves quality of life by reducing treatment burden, adverse events, and unplanned or uncoordinated care.

Keywords: Multimorbidity, Long-term conditions, Frailty, Older people.

Key Points:

- Multimorbidity is defined by two or more long-term conditions and increases with age.
- A considerable overlap can be seen between frailty and multimorbidity.
- The recent National Institute for Health and Care Excellence (NICE) guidelines on multimorbidity highlight target groups who require an individualised assessment and care plan.
- The complexity of multimorbidity in the context of frailty, dementia and polypharmacy bears a substantial healthcare burden.

Introduction

Multimorbidity is defined by the presence of two or more long-term conditions (LTCs), which are those that cannot currently be cured but can be controlled through medications or other treatments. Multimorbidity increases with both social deprivation and age, with almost a quarter of the UK population affected as a whole and two-thirds of people aged 65 years or over [1]. Compared to those with one or no LTCs, people with multimorbidity have increased risk of functional decline [2, 3], poorer quality of life [4, 5], greater health-care use [6, 7] and increased mortality [8, 9].

Numerically, most people with multimorbidity are middle-aged, and community-dwelling. Reflecting this, the concept of multimorbidity arose in the context of primary care as a remedy to both a recognised narrow focus on single diseases and as means of underscoring the need for generalism in the management of people, rather than diseases. Much of the multimorbidity research to date has focused on combinations of chronic, frequently synergistic diseases such as diabetes and cardiac disease in primary care.
Geriatricians are accustomed to managing multiple chronic conditions on a regular basis, yet until recently, there has been little to support multimorbidity as an entity in its own right. The publication of guidelines on multimorbidity by the National Institute for Health and Care Excellence (NICE) [10] and supporting editorials in both Age and Ageing [11] and the Journal of the American Geriatrics Society [12] have highlighted its importance to both clinicians and researchers, and emphasised the role of geriatricians and specialist practitioners in its recognition and management. Additionally, the NICE guidelines have contributed to advancing understanding by codifying frailty as a clinical entity in the wider context of multimorbidity.

This review will focus on recent findings in multimorbidity and discuss the interrelationship between multimorbidity and frailty, particularly in older people. Neurodegenerative disease in older people will be highlighted as an exemplar of a target group from the NICE guidelines.

**Multimorbidity: applicability to geriatricians**

Multimorbidity is of particular relevance to geriatricians, as the number of morbidities and proportion of the population with multimorbidity increases substantially with age [1]. In addition, the complexity of multimorbidity in the context of coexisting conditions such as frailty and dementia, plus associated polypharmacy that is widespread in older adults, has a considerable burden at an individual level, and major implications from a health service, social care and policy perspective (Figure 1).

**Figure 1**: Diagram to indicate the need for an approach to care that takes account of multimorbidity [10]. Reproduced with permission National Guideline Centre (2016) Multimorbidity: clinical assessment and management (NG56). Published by the National Guidelines Centre at The Royal College of Physicians, 11 St Andrews Place, Regent’s Park, London, NW1 4LE. Copyright © NGC. Reproduced by permission.
Prior to the NICE guidelines, a key difficulty in prioritising multimorbidity was that, by definition, it affects approximately 25% of the UK population, which equates to around 15 million people; this is an insurmountably large number to target for intervention [1, 11]. Furthermore, traditional multimorbidity measures such as disease counts [13] or comorbidity indices [14] may fail to characterise the common characteristics of multimorbidity in old age. A key strength of the NICE guidelines is the identification of target groups with multimorbidity who have especially high levels of complexity, so need an approach to care that takes account of multimorbidity (Box 1). The large majority of the target groups are closely aligned with the patient populations seen by geriatricians on a daily basis, for example, people who are frail in virtue of accumulated deficits that often include combinations of functional impairment, falls, coexisting physical and mental health conditions, and polypharmacy [10, 11, 15].
As advancing age is associated with increasing multimorbidity, some older people can be particularly challenged to maintain health and wellbeing with increasing number and severity of individual conditions, and associated frailty [16]. Despite significant levels of disease, however, baseline findings from the Newcastle 85+ Study demonstrated that many 85 year olds rated their health as good or very good [17], highlighting that different disease-related factors may be of particular importance. Multimorbidity may have a greater impact on overall health and well-being in some people if it is in disparate conditions; for example, conditions affecting physical and mental health compared to closely related comorbidities (such as ischaemic heart disease, hypertension and diabetes); the former encompasses neurodegenerative diseases which disproportionately affect older adults [10].

The majority of older adults have two or more LTCs [1], so use more primary and secondary care services [18] and can expect more fragmented care compared to those with only one or two recognised illnesses [6]. Care home residents are almost universally affected by multimorbidity, with a mean number of chronic conditions found to be 17 in one German study [19]. When compared with those with single chronic conditions, older adults with multimorbidity are at much greater risk of becoming care dependent, with almost a third requiring care home placement over a five year period in contrast to a quarter of the non-multimorbid population [20]. Finally in terms of relevance to geriatricians, multimorbidity increases the risk of experiencing intrusive problems such as pain, incontinence, falls, pressure ulcers and delirium. Specific diseases such as Parkinson’s disease (PD), cerebrovascular disease and peripheral artery disease appear to be especially problematic coexisting LTCs as they are associated with particularly high levels of these ageing syndromes [21].

**The overlap of multimorbidity and frailty**

Most older people with frailty have multimorbidity, but the majority of people with multimorbidity are not phenotypically frail [22], despite being at greater risk for adverse health outcomes than their age peers. Although separate concepts, it is apparent that there is a large overlap between frailty and multimorbidity [23], and this is recognised in the recent NICE guidelines [10]. At younger ages, a single disease process characteristically dominates which, over time, can become part of a wider multimorbidity complex. The accumulation of multiple long-term conditions alongside other health deficits (clinical signs, symptoms, impairments) can lead to the development of frailty, which identifies people at especially high risk of adverse outcomes such as falls, disability, nursing home

---

**Box 1: NICE ‘target groups’ of people who may benefit from an approach to care that takes account of their multimorbidity:**

- they find it difficult to manage their treatments or day-to-day activities
- they receive care and support from multiple services and need additional services
- they have both long-term physical and mental health conditions
- they have frailty or falls
- they frequently seek unplanned or emergency care
- they are prescribed multiple regular medicines.
admission, hospitalisation and mortality [15, 24] (Figure 2). Frailty can usefully be considered therefore as a method of identifying older people with multimorbidity who are especially vulnerable to a wide range of adverse outcomes that are important from an individual and societal perspective.

Importantly, established models of frailty such as the phenotype model and cumulative deficit model incorporate aspects of function such as evidence of mobility impairment or activities of daily living, which are not ordinarily incorporated into multimorbidity models. This is especially relevant because functional impairments are often targeted as a core component of evidence-based interventions to improve outcomes for older people with frailty, such as comprehensive geriatric assessment and exercise programmes. Furthermore, evidence indicates that the association between multimorbidity and mortality is lost when adjusted for functional impairment [25]. Taken together, this evidence highlights the critical importance of identifying frailty in older people with multimorbidity as a key method of targeting those who may benefit from provision of interventions to improve outcomes.

**Figure 2:** Flowchart of the evolution of a single disease process to multimorbidity, functional impairment and finally frailty

---

The underlying pathophysiology of frailty is characterised by a prominent decrease in physiological reserve and failure of homeostatic mechanisms that are more pronounced than would be expected from normal ageing [15]. It is proposed that epigenetic mechanisms, in combination with both genetic and environmental factors, generate cumulative molecular and cellular damage, triggering a cascade of further negative insults [15]. At a cellular level, alterations in the neuroendocrine production of insulin-like growth factor-1 (IGF-1) [26], testosterone [27] and cortisol [28] have been
implicated in frailty, together with abnormalities of the inflammatory response and associated changes in inflammatory cytokines [15, 29, 30]. Analogously, a recent discussion paper proposed that multimorbidity is the end result of failure of multiple physiological networks interacting with psychosocial and behavioural factors of the individual [31]. These networks include genomic, proteomic, metabolomic, neuroendocrine, immune and bioenergetics processes. Particular emphasis was placed on the autonomic nervous system, the hypothalamic-pituitary-adrenal axis and its subsequent influence on cytokine production, and on mitochondrial function; all of which may have important implications for interventions in multimorbidity [31]. This accumulating evidence has led to a proposed shift away from defining multimorbidity as a simple disease count to reflect a more widespread health deficit accumulation [10, 32].

In view of the overlap between frailty and multimorbidity, the NICE guidelines suggest that we should consider the identification of frailty as one way to identify those with multimorbidity who may benefit from a tailored approach to care [10]. In hospital outpatient settings, the use of self-reported health status, the ‘Timed Up and Go’ test, gait speed, PRISMA-7 questionnaire or self-reported physical activity were all recommended tools for identifying frailty. Although ostensibly pragmatic, the difficulty faced with the use of frailty as a targeting characteristic in the NICE guidelines is that these physical performance measures of frailty are not advocated in acute settings, thereby limiting these instruments for geriatricians working with in-patients.

The use of frailty to target interventions for people with multimorbidity was also prominent in the NICE guideline research recommendations. For example, frailty was identified as one method of identifying a target group for a clinical trial evaluation of a holistic assessment and management intervention for people in the community living with high levels of multimorbidity. Furthermore, frailty was identified as a method of targeting for future randomised controlled trial evaluations of deprescribing interventions to reduce treatment burden for people with multimorbidity.

**Multimorbidity in long-term conditions: the example of neurodegenerative disease and multimorbidity**

The majority of people with one LTC have multiple LTCs, yet most clinical guidelines focus almost exclusively on single conditions [33]. If guidelines are followed for each comorbidity in older adults, invariably polypharmacy ensues, leading to probable drug-drug interactions and their associated consequences, which may be more pronounced in frailer and/or cognitively impaired people [33, 34]. The preventative effect of each individual drug is likely to be less in those with multiple drug use, and is reduced again in those with a limited life expectancy [33]. Additionally, the evidence for the individual guidelines often comes from younger, fitter patients, as older adults with multimorbidity are often excluded from clinical trials, limiting the generalisability to the typical population seen by practitioners working with older people [35, 36].

Neurodegenerative diseases provide a useful example of the NICE guideline target group of people with multimorbidity living with physical and mental health problems. Parkinson’s disease (PD) is the second commonest neurodegenerative disease in economically developed countries and is an example of an age-related multisystem disease encompassing both physical and mental health problems such as dementia [37], mild cognitive impairment (MCI) [38], depression [39] and psychosis [40]. A recent study on the impact of a large number of differing comorbidities on quality of life in people with multimorbidity reported that PD had the most pronounced negative effect [41],
whilst additional work in Germany on multimorbidity and long-term care dependency highlighted that the conditions with the highest risk for care home admission were PD and dementia [20]. General polypharmacy is common in PD, with UK primary health-care data demonstrating that 19.2% of PD patients aged 55 and over are on 10 or more medications compared to 6.2% of controls [MacLean G et al, under review]. The same study showed that compared to 22.9% of controls, only 7.4% of PD subjects had no other comorbidities. Taken together, these studies illustrate that multimorbidity in PD also has a significant impact on healthcare expenditure in terms of institutionalisation and medication use, with evidence that excess expenditures associated with PD are at least partly driven by coexisting LTCs [42]. Moreover, there is evidence that multimorbidity may also drive disease progression or complications in PD. One study found evidence for a small negative effect of cardiovascular and diabetes comorbidities on cognition, which was independent of age, PD duration and severity, and medication use [43]. In the general (non-PD) population, multimorbidity has been associated with greater longitudinal risk of MCI or dementia [44], and can accelerate cognitive decline in those with underlying dementia [45].

Managing multimorbidity

Familiar to geriatricians, the NICE guidelines advocate an approach to care that takes account of multimorbidity, involving a personalised assessment and the development of an individualised management plan [10]. The aim is to improve quality of life by reducing treatment burden, adverse events, and unplanned or uncoordinated care. The approach takes account of a person’s individual needs, preferences for treatments, health priorities and lifestyle. It aims to improve coordination of care across services, particularly if this has become fragmented. This approach should be considered if the person requests it or if any of the issues apply as outlined in box 1 [10].

The NICE guidelines expand on a previous approach detailed by the American Geriatrics Society (AGS) [46]. The guidelines encouraged the use of a treatment plan in primary care for older adults with multiple chronic conditions, where consideration had been given to prognosis, treatment/condition interactions, benefits and harms of treatments, and subsequent reassessment [46]. Although the AGS and NICE guidelines do not specifically consider situations in which patients are unable to participate in care discussions due to acute severe illness, delirium, dementia, or severe frailty, a proactive approach to treatment plan development prior to crises or loss of capacity should be considered good practice.

An additional challenge in the management of multimorbidity is the relative paucity of evidence to date on the effectiveness of interventions to improve outcomes in this construct, in contrast to the more robust evidence available for a Comprehensive Geriatric Assessment in the management of frailty [47]. A recent Cochrane review of interventions in multimorbidity in primary care and community settings highlighted the limited number of randomised controlled trials (RCTs) and their mixed results [48]. The interventions were largely focussed on care delivery, which translated into probable improvements in mental health outcomes and patient-reported outcomes, but not into clinical outcomes or health service use. Further intervention studies are required in this area.

A more nuanced approach to multimorbidity management has been highlighted in a recent interesting discussion paper [31]. The authors emphasise the importance of bio-psycho-social factors in the context of physiological dysregulation of the neuroendocrine, immune and mitochondrial systems. They postulate that future care of the multimorbid patient might include
small molecule therapeutics to target the complex molecular and cellular dysfunction, together with environmental factors such as health behaviour, emotional and social support and stress management [31].

Conclusions and future directions
Multimorbidity is a highly prevalent, highly relevant concept for specialists working with older people. Although research has been traditionally centred in primary care, multimorbidity is synonymous with the challenges faced by geriatricians, where the complexity of disease processes and polypharmacy is particularly onerous for individuals, their families and for the health service. While previous research has investigated the cross-sectional overlap between comorbidity and frailty, there is a paucity of research on the temporal relationships between single LTCs, multimorbidity, frailty and disability. Furthermore, there is a paucity of research involving people with neurodegenerative disease who have multiple LTCs, with the exception of limited work in dementia.

The development of a cohesive research strategy on how to meet the needs of older people with multimorbidity is a key priority. In the UK, the National Institute for Health Research has prioritised this research area, indicating ongoing commitment to strengthening the evidence base for older people with complex health needs (http://www.nihr.ac.uk/funding-and-support/themed-calls/). NICE has recommended that key topics for research in this field are the organisation of care, holistic assessment in the community, stopping preventive medicines and predicting life expectancy [10]. These key topic areas require further refinement to align with the priorities of older people, the public and health care practitioners; views which are currently actively being sought and prioritised in a James Lind Alliance priority setting partnership (https://research.ncl.ac.uk/jlpprioritysetting/ageingmultimorbidity/).

Future research should focus on these areas, with definitive RCTs of suitably targeted interventions, together with the exploration of putative common underlying physiological process to identify novel therapeutic targets. As geriatricians, we are ideally placed to advance this field of research and ensure that the new horizon in multimorbidity is informed by a robust evidence base that is aligned with the complex health needs of older people.

Acknowledgements

The research was supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre based at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Conflicts of interest

Kenneth Rockwood is President and Chief Science Officer of DGI Clinical, which has contracts with pharma on individualized outcome measurement. In July 2015 he gave a lecture at the Alzheimer Association International Conference in a symposium sponsored by Otsuka and Lundbeck. At that
time he presented at an Advisory Board meeting for Nutricia. In 2017 he attended an advisory board meeting for Lundbeck. He is a member of the Research Executive Committee of the Canadian Consortium on Neurodegeneration in Aging, which is funded by the Canadian institutes of Health Research, with additional funding from the Alzheimer Society of Canada and several other charities, as well as from Pfizer Canada and Sanofi Canada. He receives career support from the Dalhousie Medical Research Foundation as the Kathryn Allen Weldon Professor of Alzheimer Research, and research support from the Nova Scotia Health Research Foundation, the Capital Health Research Fund and the Fountain Family Innovation Fund of the Nova Scotia Health Authority Foundation. The other authors have no conflicts of interest to report.

**Declarations of Sources of Funding:** None.

**References**


